Please assess the completion status of the following clinical trial:

Trial Title: BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and non-pregnant female subjects~* 18 years of age or older~* Received aspirin, clopidogrel, heparin (unfractionated or low molecular weight \[LMW\]) and eptifibatide~* Had a successful PCI procedure with at least one stent deployed~* Availability of a hospital bed~Exclusion Criteria:~* Use of alternative anti-thrombin therapy during PCI (e.g. bivalirudin)~* High risk patients:~* Acute ST elevation MI \< 48 hours (either direct PCI or rescue PCI)~* Unprotected left main PCI~* Obvious large thrombus on angiography~* Use of rotablation, atherectomy, or thrombectomy devices~* Unsatisfactory PCI results:~* Final thrombolysis in myocardial infarction (TIMI) flow \< 3~* High grade dissection (\> type B, if not completely resolved at completion of PCI)~* Evident or suspected thrombus~* Distal embolization~* Suboptimal stenting (\> 20% residual stenosis)~* Side branch closure (≥ 1.5 mm branch or with associated symptoms)~* Abrupt closure during procedure (if prolonged \> 15 min or not resolved at completion of PCI)~* Clinical instability~* Prolonged ischemia during PCI (\> 15 min)~* Increased hazard of eptifibatide infusion:~* Unsatisfactory deployment of a closure device (if used)~* Large peri-procedure hematoma making the continuation of eptifibatide hazardous~* Any condition that will increase the hazard of continuing eptifibatide~* Operator discretion~* No informed consent~* Active participation in other research studies (unless with special exemption)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18 Hour infusion (Type: ACTIVE_COMPARATOR): None
- 4 hour infusion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).